DNMT3A and acute myeloid leukemia: In recent years, as research into the pathogenesis of DNMT3A mutations in AML has continued, therapeutic strategies targeting DNMT3A mutation-dependent DNA methylation and downstream molecules or pathways have emerged, showing great promise for application in the clinical setting.